Emerald Mutual Fund Advisers Trust’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-85,696
Closed -$3.82M – 327
2020
Q1
$3.82M Sell
85,696
-289,150
-77% -$14.6M 0.24% 114
2019
Q4
$18M Buy
374,846
+11,434
+3% +$486K 0.74% 47
2019
Q3
$12.3M Buy
363,412
+8,664
+2% +$377K 0.54% 67
2019
Q2
$16M Buy
354,748
+80,036
+29% +$3.16M 0.63% 54
2019
Q1
$10.3M Buy
274,712
+67,359
+32% +$2.26M 0.41% 87
2018
Q4
$7.12M Hold
207,353
– – 0.33% 103
2018
Q3
$9.75M Buy
+207,353
New +$8.58M 0.33% 110
2016
Q1
– Sell
-112,678
Closed -$3.65M – 275
2015
Q4
$3.65M Buy
+112,678
New +$3.32M 0.19% 137

Other funds holding PTCT

Emerald Mutual Fund Advisers Trust's PTCT Position: Q2 2020 in Review

Emerald Mutual Fund Advisers Trust sold out of PTC Therapeutics (PTCT) in Q2 2020, closing a stake of 85,696 shares — an estimated $3.82M sold.

Emerald Mutual Fund Advisers Trust first reported a position in PTCT in Q4 2015 and held it in 8 quarters. The position peaked at $18M in Q4 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q2 2020.

  • Emerald Mutual Fund Advisers Trust reported no remaining PTC Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 85,696 PTC Therapeutics shares in Q2 2020, an estimated $3.82M.
  • Emerald Mutual Fund Advisers Trust first reported a position in PTC Therapeutics in Q4 2015 and held it in 8 quarters.
  • Emerald Mutual Fund Advisers Trust's PTC Therapeutics position peaked at $18M in Q4 2019.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2020.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2020, filed 28 Jul 2020.